摘要目的 观察miR-369-3p对膀胱癌细胞EJ和5637中血管内皮细胞生长因子C(VEGFC)基因的调控作用,并观察其对细胞增殖及凋亡的影响.方法 转染miR-NC(对照组)或转染miR-369-3p(观察组)至膀胱癌细胞株EJ和5637;采用Targetscan靶基因预测软件预测miR-369-3p的靶基因;采用荧光实时定量聚合酶链反应(qPCR)检测VEGFC mRNA表达变化;Western blotting检测VEGFC、p-Raf-1和磷酸化细胞外信号调节激酶1/2(p-ERK1/2)在蛋白水平的变化;采用细胞计数试剂盒(CCK-8法)和克隆形成实验检测miR-369-3p对膀胱癌细胞增殖的影响;采用流式细胞术检测miR-369-3p对细胞凋亡的影响.结果 转染miR-369-3p后,EJ、5637细胞中VEGFC在mRNA水平和蛋白水平的表达均明显下降(P＜0.05),p-Raf-1和p-ERK1/2蛋白表达明显降低,细胞的增殖能力明显降低(P＜0.05),细胞形成的克隆数明显减少(P＜0.05),细胞凋亡明显增加(P＜0.01).结论 miR-369-3p可通过干扰VEGFC基因的表达,抑制膀胱癌细胞的增殖及促进膀胱癌细胞的凋亡,可能为膀胱癌的生物治疗提供一个新的靶标.

abstractsObjective To observe the effect of miR-369-3p on vascular endothelial growth factor C (VEGFC) gene in bladder cancer cells EJ and 5637 and observe its effect on cell proliferation and apoptosis.Methods Bladder cancer cell lines EJ and 5637 were transfected with miR-NC (control group) or transfected with miR-369-3p (experimental group).The target gene of miR-369-3p was predicted by Targets can target gene prediction software.Fluorescence real-time quantitative polymerase chain reaction (qPCR) was used to detect the changes of VEGFC at mRNA level.The changes of VEGFC,p-Raf-1 and phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) at the protein level were detected by Western blotting.The effect of miR-369-3p on the proliferation of bladder cancer cells was detected by cell counting kit (CCK-8) and clone formation experiment.The effect of miR-369-3p on apoptosis was detected by flow cytometry.Results After transfection with miR-369-3p,the expression of VEGFC at mRNA and protein levels was significantly decreased (P ＜ 0.05),the expression of p-Raf-1 and p-ERK1/2 protein was significantly decreased,the cell proliferation ability was significantly decreased (P ＜ 0.05),the number of clones formed was significantly decreased (P ＜ 0.05) and the apoptosis was significantly increased (P ＜ 0.01).Conclusions miR-369-3p can inhibit the proliferation and promote the apoptosis of bladder cancer cells by interfering with the expression of VEGFC gene,which may provide a new target for the biological therapy of bladder cancer.